- Home
- CAPR vs MCFT Comparison
CAPR vs MCFT Comparison
Compare CAPR & MCFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MCFT
- Stock Information
- Founded
- CAPR 2005
- MCFT 1968
- Country
- CAPR United States
- MCFT United States
- Employees
- CAPR N/A
- MCFT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MCFT Marine Transportation
- Sector
- CAPR Health Care
- MCFT Industrials
- Exchange
- CAPR Nasdaq
- MCFT Nasdaq
- Market Cap
- CAPR 324.6M
- MCFT 315.8M
- IPO Year
- CAPR N/A
- MCFT 2015
- Fundamental
- Price
- CAPR $6.28
- MCFT $21.94
- Analyst Decision
- CAPR Strong Buy
- MCFT Hold
- Analyst Count
- CAPR 8
- MCFT 6
- Target Price
- CAPR $24.75
- MCFT $21.50
- AVG Volume (30 Days)
- CAPR 1.4M
- MCFT 161.0K
- Earning Date
- CAPR 08-11-2025
- MCFT 08-27-2025
- Dividend Yield
- CAPR N/A
- MCFT N/A
- EPS Growth
- CAPR N/A
- MCFT N/A
- EPS
- CAPR N/A
- MCFT 0.43
- Revenue
- CAPR $13,392,150.00
- MCFT $284,203,000.00
- Revenue This Year
- CAPR N/A
- MCFT $15.58
- Revenue Next Year
- CAPR $6,061.53
- MCFT $4.25
- P/E Ratio
- CAPR N/A
- MCFT $33.75
- Revenue Growth
- CAPR N/A
- MCFT N/A
- 52 Week Low
- CAPR $3.98
- MCFT $14.39
- 52 Week High
- CAPR $23.40
- MCFT $23.50
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- MCFT 60.94
- Support Level
- CAPR $6.17
- MCFT $20.83
- Resistance Level
- CAPR $7.30
- MCFT $23.50
- Average True Range (ATR)
- CAPR 0.43
- MCFT 0.82
- MACD
- CAPR -0.11
- MCFT 0.18
- Stochastic Oscillator
- CAPR 4.53
- MCFT 60.61
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MCFT MasterCraft Boat Holdings Inc.
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.